BR112015032539A2 - compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase - Google Patents
compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinaseInfo
- Publication number
- BR112015032539A2 BR112015032539A2 BR112015032539A BR112015032539A BR112015032539A2 BR 112015032539 A2 BR112015032539 A2 BR 112015032539A2 BR 112015032539 A BR112015032539 A BR 112015032539A BR 112015032539 A BR112015032539 A BR 112015032539A BR 112015032539 A2 BR112015032539 A2 BR 112015032539A2
- Authority
- BR
- Brazil
- Prior art keywords
- raf kinase
- urea compounds
- fused tricyclic
- dimer
- kinase inhibitors
- Prior art date
Links
- 150000003672 ureas Chemical class 0.000 title abstract 2
- 102000009929 raf Kinases Human genes 0.000 title 2
- 108010077182 raf Kinases Proteins 0.000 title 2
- 239000000539 dimer Substances 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
a presente invenção refere-se a compostos ureia tricíclicos fundidos e sais dos mesmos, composições dos mesmos e métodos de uso dos mesmos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013078338 | 2013-06-28 | ||
| CNPCT/CN2013/078338 | 2013-06-28 | ||
| PCT/CN2014/080983 WO2014206343A1 (en) | 2013-06-28 | 2014-06-27 | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015032539A2 true BR112015032539A2 (pt) | 2017-07-25 |
| BR112015032539B1 BR112015032539B1 (pt) | 2022-07-12 |
Family
ID=52141106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015032539-4A BR112015032539B1 (pt) | 2013-06-28 | 2014-06-27 | Compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase e composição farmacêutica compreendendo os referidos compostos |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9670203B2 (pt) |
| EP (1) | EP3013798B1 (pt) |
| JP (4) | JP6380861B2 (pt) |
| KR (1) | KR102272606B1 (pt) |
| CN (2) | CN105452223B (pt) |
| AU (1) | AU2014301816B2 (pt) |
| BR (1) | BR112015032539B1 (pt) |
| CA (1) | CA2916543C (pt) |
| DK (1) | DK3013798T3 (pt) |
| EA (1) | EA029412B1 (pt) |
| ES (1) | ES2686821T3 (pt) |
| HK (1) | HK1217485A1 (pt) |
| IL (1) | IL242973A0 (pt) |
| MX (1) | MX362582B (pt) |
| NZ (1) | NZ716392A (pt) |
| PT (1) | PT3013798T (pt) |
| SG (1) | SG11201600147TA (pt) |
| WO (1) | WO2014206343A1 (pt) |
| ZA (1) | ZA201600513B (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US9670231B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| JP6380861B2 (ja) | 2013-06-28 | 2018-08-29 | ベイジーン リミテッド | Ｒａｆキナ−ゼおよび／またはＲａｆキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| DK3386591T3 (da) | 2015-12-09 | 2020-09-28 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and uses thereof |
| ES2950348T3 (es) | 2015-12-09 | 2023-10-09 | Novartis Ag | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos |
| US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| EP3830092B1 (en) | 2018-08-03 | 2023-05-03 | Novartis AG | Heteroaromatic nmda receptor modulators and uses thereof |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN111484490A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州有限公司 | 适合大规模生产b-raf激酶二聚体抑制剂的方法 |
| CN111484489B (zh) * | 2019-01-25 | 2023-05-23 | 百济神州(北京)生物科技有限公司 | 无定形的b-raf激酶二聚体抑制剂 |
| TW202043225A (zh) * | 2019-01-25 | 2020-12-01 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| CN111484488A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州(北京)生物科技有限公司 | 一种b-raf激酶二聚体抑制剂的稳定结晶形式a |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021072028A1 (en) * | 2019-10-08 | 2021-04-15 | The Brigham And Women's Hospital, Inc. | Activators of heme regulated inhibitor kinase (hri) |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JP2023529867A (ja) | 2020-06-05 | 2023-07-12 | キネート バイオファーマ インク． | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
| WO2022216680A1 (en) | 2021-04-05 | 2022-10-13 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2022226182A1 (en) | 2021-04-22 | 2022-10-27 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023240178A1 (en) * | 2022-06-08 | 2023-12-14 | Mapkure, Llc | Methods of treating cancer with a b-raf inhibitor |
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2024073364A1 (en) * | 2022-09-26 | 2024-04-04 | Beigene, Ltd. | Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer |
| US20240122881A1 (en) * | 2022-10-14 | 2024-04-18 | Springworks Therapeutics, Inc. | Combination for use in treating cancers |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100733D0 (sv) * | 2001-03-05 | 2001-03-05 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| CN1694700A (zh) * | 2002-09-05 | 2005-11-09 | 美迪维尔公司 | 非核苷逆转录酶抑制剂 |
| WO2005062795A2 (en) | 2003-12-19 | 2005-07-14 | Plexxikon, Inc. | Compounds and methods for development of ret modulators |
| CN101087787A (zh) | 2004-12-23 | 2007-12-12 | 霍夫曼-拉罗奇有限公司 | 苯甲酰胺衍生物，它们的制备及作为药剂的应用 |
| CA2632512A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| AU2007254325B2 (en) | 2006-05-15 | 2012-05-10 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP2064213A1 (en) | 2006-09-06 | 2009-06-03 | F. Hoffmann-La Roche AG | Heteroaryl derivatives as protein kinase inhibitors |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| GB0807609D0 (en) * | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| CN102947290B (zh) | 2010-01-27 | 2015-05-27 | 内尔维安诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物 |
| CN103596926B (zh) | 2011-12-31 | 2015-11-25 | 百济神州有限公司 | 作为raf激酶抑制剂的稠合三环化合物 |
| US9670231B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| JP6380861B2 (ja) | 2013-06-28 | 2018-08-29 | ベイジーン リミテッド | Ｒａｆキナ−ゼおよび／またはＲａｆキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
-
2014
- 2014-06-27 JP JP2016522232A patent/JP6380861B2/ja active Active
- 2014-06-27 NZ NZ716392A patent/NZ716392A/en unknown
- 2014-06-27 CN CN201480037041.6A patent/CN105452223B/zh active Active
- 2014-06-27 DK DK14818636.4T patent/DK3013798T3/en active
- 2014-06-27 SG SG11201600147TA patent/SG11201600147TA/en unknown
- 2014-06-27 PT PT14818636T patent/PT3013798T/pt unknown
- 2014-06-27 CN CN201811172580.7A patent/CN109369671B/zh active Active
- 2014-06-27 KR KR1020167001854A patent/KR102272606B1/ko active IP Right Grant
- 2014-06-27 MX MX2016000143A patent/MX362582B/es active IP Right Grant
- 2014-06-27 WO PCT/CN2014/080983 patent/WO2014206343A1/en active Application Filing
- 2014-06-27 BR BR112015032539-4A patent/BR112015032539B1/pt active IP Right Grant
- 2014-06-27 CA CA2916543A patent/CA2916543C/en active Active
- 2014-06-27 ES ES14818636.4T patent/ES2686821T3/es active Active
- 2014-06-27 AU AU2014301816A patent/AU2014301816B2/en active Active
- 2014-06-27 US US14/901,634 patent/US9670203B2/en active Active
- 2014-06-27 EA EA201690098A patent/EA029412B1/ru not_active IP Right Cessation
- 2014-06-27 EP EP14818636.4A patent/EP3013798B1/en active Active
-
2015
- 2015-12-20 IL IL242973A patent/IL242973A0/en active IP Right Grant
-
2016
- 2016-01-22 ZA ZA2016/00513A patent/ZA201600513B/en unknown
- 2016-05-12 HK HK16105443.4A patent/HK1217485A1/zh unknown
-
2017
- 2017-04-28 US US15/581,728 patent/US9920055B2/en active Active
-
2018
- 2018-01-29 US US15/882,067 patent/US10208038B2/en active Active
- 2018-07-19 JP JP2018135807A patent/JP6707584B2/ja active Active
-
2019
- 2019-01-09 US US16/243,301 patent/US10562899B2/en active Active
-
2020
- 2020-05-20 JP JP2020088185A patent/JP6889311B2/ja active Active
-
2021
- 2021-05-20 JP JP2021085486A patent/JP7207629B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015032539A2 (pt) | compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase | |
| BR112015028171A8 (pt) | Inibidores de acc e seu uso | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| BR112016006319A2 (pt) | inibidores de irak e usos dos mesmos | |
| CR20150462A (es) | Inhibidores de erk y sus usos | |
| ECSP15043696A (es) | Compuestos de heteroarilo y sus usos | |
| BR112015028173A2 (pt) | inibidores de acc e usos dos mesmos | |
| CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
| BR112017005266A2 (pt) | inibidores de mk2 e uso dos mesmos | |
| UY35330A (es) | Amidas heterocíclicas como inhibidores de cinasas | |
| BR112017013767A2 (pt) | uso de picolinamidas como fungicidas | |
| BR112018003343A2 (pt) | compostos heteroarila como inibidores de irak e usos dos mesmos | |
| BR112016006366A2 (pt) | uso de picolinamidas macrocíclicas como fungicidas | |
| EA201692219A1 (ru) | Способы получения противовирусных соединений | |
| EA201591137A1 (ru) | Ингибиторы mk2 и их применения | |
| EA201591960A1 (ru) | Ингибиторы акк и их применение | |
| BR112018003812A2 (pt) | compostos de heteroarila como inibidores de irak e usos dos mesmos | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| EA201591962A1 (ru) | Ингибиторы акк и их применение | |
| EA201491305A1 (ru) | Конденсированные трициклические соединения в качестве ингибиторов raf киназы | |
| DOP2015000059A (es) | Amino-quinolinas como inhibidores de cinasa | |
| BR112017028549A2 (pt) | derivados de pirimidina como inibidores de btk e usos dos mesmos | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| BR112018011525A2 (pt) | inibidores da tirosina quinase de bruton e métodos de seu uso | |
| BR112014030720A8 (pt) | composto, composição farmacêutica e usos de inibidores de fbx03 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/06/2014, OBSERVADAS AS CONDICOES LEGAIS |